◆ NeutralMDLN
MDLN ALERT: HBSS Probes Medline (MDLN) After Reports Reveal Undisclosed Manufacturing Violations and Failed Contamination Investigations
GlobeNewswire Inc.·
Hagens Berman has launched an investigation into Medline Inc. (NASDAQ: MDLN) for allegedly misleading investors about manufacturing quality controls and FDA compliance. An FDA warning letter revealed systemic contamination failures and inadequate corrective actions between June 2023 and August 2025. The disclosure prompted a $2.2 billion market capitalization decline.
Read Full Article at GlobeNewswire Inc. →